Cortigent is a pre-revenue medical device company developing implantable neurostimulation systems to restore vision and motor movement. Spun out from Vivani Medical, the company focuses on two primary applications for its proprietary hardware platform. Its lead product, the Orion Visual Cortical Prosthesis System, is a brain-surface implant designed to provide artificial vision to blind individuals. The system uses a video camera to capture images and transmits electrical pulses to an electrode array on the visual cortex. Cortigent's second product, the Stroke Recovery System, targets the motor cortex to accelerate the recovery of limb movement in stroke patients. Both devices utilize a non-penetrating electrode design that remains on the surface of the brain rather than entering tissue. The company’s business model centers on the one-time sale of these medical devices, with revenue generation contingent on obtaining FDA Class III premarket approval and securing reimbursement from government and private insurers. Cortigent’s strategy involves leveraging its core neurostimulation hardware across multiple indications to reduce manufacturing and regulatory costs. The company plans to begin pivotal clinical trials for its vision system in late 2027, with a targeted commercial launch in 2030, while the stroke system is scheduled for launch in 2031. Capital from its IPO and support from Vivani Medical fund current operations.